-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 11, Ealing Pharmaceuticals announced that it had recently received a drug registration approval document approved by the Ministry of Health of Mongolia, approving the registration of its Lianhua Qing plague capsules in accordance with Mongolian drug standards.
products for the national basic drug catalog and national health insurance catalogue (Class A) varieties, mainly used for cold, influenza-related diseases treatment.
announcement, Lianhua Qing plague products have been repeatedly included in the National Health And Health Commission, the State Administration of Traditional Chinese Medicine cold, influenza-related disease diagnosis and treatment program.
2020 Lianhua Qing plague capsules/particles are listed as the National Health And Health Commission and the State Administration of Traditional Chinese Medicine jointly issued the "new coronavirus pneumonia diagnosis and treatment program" (trial 4/5/6/7/8 version) recommended medication.
April 12, 2020, the State Drug Administration approved lianhua Qing plague capsules/particles to add a new adaptation of "new coronavirus pneumonia light, common type" on the basis of the original approved adaptation.
2019, The company achieved operating income of 1.703 billion yuan, accounting for 29.24% of its total operating income.
the first three quarters of 2020, Lianhua Qing plague products achieved operating income of 2.871 billion yuan, accounting for 44.52 percent of total operating income.
